Jason O’Byrne
Directeur Financier/CFO chez CARIBOU BIOSCIENCES, INC.
Fortune : 222 682 $ au 30/04/2024
Profil
Jason V.
O’Byrne is currently the Chief Financial Officer at Caribou Biosciences, Inc. He previously worked as the Regional Controller at General Chemical Corp.
from 2002 to 2005 and as the Senior Vice President-Finance at Astellas Gene Therapies, Inc. from 2019 to 2021.
Mr. O’Byrne completed his undergraduate degree at the University of British Columbia and holds an MBA from The Leonard N Stern School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 20/02/2024 | 59 224 ( 0,07% ) | 222 682 $ | 30/04/2024 |
Postes actifs de Jason O’Byrne
| Sociétés | Poste | Début |
|---|---|---|
| CARIBOU BIOSCIENCES, INC. | Directeur Financier/CFO | 09/02/2021 |
Anciens postes connus de Jason O’Byrne
| Sociétés | Poste | Fin |
|---|---|---|
| AUDENTES THERAPEUTICS, INC. | Directeur Financier/CFO | 01/02/2021 |
General Chemical Corp.
 General Chemical Corp. Industrial SpecialtiesProcess Industries General Chemical Corp. supplies specialty chemicals. Its soldering fluxes are designed to reduce or virtually eliminate corrosion in soldered joints. The firm’s paint strippers are used for substrate such as aluminum, ferrous metals and other surfaces. The company was founded in 1980 and is headquartered in Brighton, MI. | Corporate Officer/Principal | 01/01/2005 |
Formation de Jason O’Byrne
| The Leonard N Stern School of Business | Masters Business Admin |
| University of British Columbia | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CARIBOU BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Astellas Gene Therapies, Inc.
 Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
General Chemical Corp.
General Chemical Corp. Industrial SpecialtiesProcess Industries General Chemical Corp. supplies specialty chemicals. Its soldering fluxes are designed to reduce or virtually eliminate corrosion in soldered joints. The firm’s paint strippers are used for substrate such as aluminum, ferrous metals and other surfaces. The company was founded in 1980 and is headquartered in Brighton, MI. | Process Industries |
